Viking Therapeutics’ Promising Results for Obesity Treatment
Company Announcements

Viking Therapeutics’ Promising Results for Obesity Treatment

Viking Therapeutics ( (VKTX) ) just unveiled an announcement.

Viking Therapeutics has presented promising data from its VK2735 obesity program at ObesityWeek® 2024, showcasing up to 8.2% weight loss from baseline with an oral formulation over 28 days. The treatment demonstrated strong tolerability, with mild GI-related side effects, and the potential for longer-term weight loss. These findings are significant for those exploring innovative solutions in metabolic disorder treatments, with both oral and subcutaneous forms of VK2735 showing durable effects.

See more data about VKTX stock on TipRanks’ Stock Analysis page.

Related Articles
Samuel O'BrientEli Lilly (NYSE:LLY) Stock Falls as Competitors Report Progress
TheFlyAstraZeneca says experimental obesity pill ‘competitive,’ Bloomberg reports
TheFlyUnusually active option classes on open November 4th
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App